Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects With Age-Related Cognitive Decline
Phase of Trial: Phase I
Latest Information Update: 11 May 2017
At a glance
- Drugs GSK 2981710 (Primary)
- Indications Memory disorders
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
- 01 Nov 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.